PLoS ONE (Jan 2021)

Aerosol SARS-CoV-2 in hospitals and long-term care homes during the COVID-19 pandemic.

  • Gary Mallach,
  • Samantha B Kasloff,
  • Tom Kovesi,
  • Anand Kumar,
  • Ryan Kulka,
  • Jay Krishnan,
  • Benoit Robert,
  • Michaeline McGuinty,
  • Sophia den Otter-Moore,
  • Bashour Yazji,
  • Todd Cutts

DOI
https://doi.org/10.1371/journal.pone.0258151
Journal volume & issue
Vol. 16, no. 9
p. e0258151

Abstract

Read online

BackgroundFew studies have quantified aerosol concentrations of SARS-CoV-2 in hospitals and long-term care homes, and fewer still have examined samples for viability. This information is needed to clarify transmission risks beyond close contact.MethodsWe deployed particulate air samplers in rooms with COVID-19 positive patients in hospital ward and ICU rooms, rooms in long-term care homes experiencing outbreaks, and a correctional facility experiencing an outbreak. Samplers were placed between 2 and 3 meters from the patient. Aerosol (small liquid particles suspended in air) samples were collected onto gelatin filters by Ultrasonic Personal Air Samplers (UPAS) fitted with ResultsIn total, 138 samples were collected from 99 rooms. RNA samples were positive in 9.1% (6/66) of samples obtained with the UPAS 2.5μm samplers, 13.5% (7/52) with the UPAS 10μm samplers, and 10.0% (2/20) samples obtained with the Coriolis samplers. Culturable virus was not recovered in any samples. Viral RNA was detected in 15.1% of the rooms sampled. There was no significant difference in viral RNA recovery between the different room locations or samplers. Method development experiments indicated minimal loss of SARS-CoV-2 viability via the personal air sampler operation.